Market Assessment, Non Small Cell Lung Cancer Pharmacor G7 2014 Report

Last Updated 20 October 2014
Biomarker- and histology-driven prescribing is standard practice in the treatment of non-small-cell lung cancer (NSCLC) across the major pharmaceutical markets. The treatment of NSCLC patients including that of molecularly defined subpopulations continues to evolve, driven by the development of novel agents and increasingly, associated biomarkers and companion diagnostics. Codeveloping a drug and a companion diagnostic is one of the most promising avenues for commercial success. Several underserved areas of high unmet need offer significant commercial opportunity for innovative agents.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Non-Small-Cell Lung Cancer | Pharmacor | G7 | 2014

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast

Biomarkers In Oncology – Access & Reimbursement – Detailed, Expanded Analysis: Biomarkers In Oncology – Non-Small-Cell Lung Cancer, Breast Cancer, And Colorectal Cancer (US)

Non-Small-Cell Lung Cancer – Unmet Need – Detailed, Expanded Analysis: EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)

Non-Small-Cell Lung Cancer – Geographic Focus: China – Non-Small-Cell Lung Cancer – China In-Depth (China)

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)